Therefore, the enhanced mobilization of myeloid cells, or TAMs, and their subsequent recruitment to the tumors are likely to contribute to the compensatory or alternative pro-angiogenic programs that render a tumor refractory to the anti-angiogenic blockade by VEGF antibodies [133]. This evidence concerns the gene VEGFA and neoplasm.